/HLOSF

HLOSF Stock - Healios K.K.

Q: What is the analyst price target for HLOSF?

Analyst price target information is not currently available for HLOSF.

Q: What is HLOSF's market cap?

Market capitalization information is not currently available for HLOSF.

Healthcare|Biotechnology|OTC

$2.31+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.54

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HLOSF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.50

52W High$4.45

52W Low$0.96

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$560.00M	$121.00M	$90.00M	$41.00M	$27.00M
Gross Profit	$432.00M	$108.00M	$90.00M	$41.00M	$27.00M
Gross Margin	77.1%	89.3%	100.0%	100.0%	100.0%
Operating Income	$-2,843,000,000	$-3,379,000,000	$-5,179,000,000	$-5,384,000,000	$-4,184,000,000
Net Income	$-4,235,000,000	$-3,823,000,000	$-5,170,000,000	$-4,912,000,000	$-5,513,000,000
Net Margin	-756.3%	-3159.5%	-5744.4%	-11980.5%	-20418.5%
EPS	$-47.87	$-56.22	$-90.69	$-93.40	$-107.21

Company Overview

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.

Visit Website

Earnings History & Surprises

HLOSF

Beat Rate

50%

Last 18 quarters

Avg Surprise

-160.6%

EPS vs Estimate

Beats / Misses

9/9

Last 12 quarters

Latest EPS

$0.00

Q4 2025

EPS Surprise History

Q3 23

+26.7%

$-0.07vs$-0.09

Q1 24

-60.1%

$-0.17vs$-0.10

Q2 24

-249.6%

$-0.19vs$-0.05

Q3 24

-20.6%

$-0.04vs$-0.03

Q4 24

-46.2%

$-0.12vs$-0.08

Q1 25

+127.7%

$0.02vs$-0.07

Q2 25

+8.0%

$-0.18vs$-0.19

Q4 25

-99.5%

$0.00vs$0.04

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 13, 2025	$0.04	$0.00	-99.5%	✗ MISS
Q2 2025	May 13, 2025	$-0.19	$-0.18	+8.0%	✓ BEAT
Q1 2025	Feb 12, 2025	$-0.07	$0.02	+127.7%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.08	$-0.12	-46.2%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.03	$-0.04	-20.6%	✗ MISS
Q2 2024	May 13, 2024	$-0.05	$-0.19	-249.6%	✗ MISS
Q1 2024	Feb 14, 2024	$-0.10	$-0.17	-60.1%	✗ MISS
Q3 2023	Sep 30, 2023	$-0.09	$-0.07	+26.7%	✓ BEAT
Q2 2023	Jun 30, 2023	$-0.11	$-0.07	+35.0%	✓ BEAT
Q1 2023	Mar 31, 2023	$-0.10	$-0.09	+13.5%	✓ BEAT
Q1 2023	Feb 14, 2023	$4.04	$-19.54	-583.7%	✗ MISS
Q4 2022	Nov 14, 2022	$-12.42	$-12.30	+1.0%	✓ BEAT
Q3 2022	Aug 9, 2022	$-1.54	$-32.64	-2019.5%	✗ MISS
Q2 2022	May 10, 2022	$-10.97	$-26.48	-141.4%	✗ MISS
Q1 2022	Feb 14, 2022	$-49.21	$-22.04	+55.2%	✓ BEAT
Q4 2021	Nov 12, 2021	$-28.93	$-34.78	-20.2%	✗ MISS
Q3 2021	Aug 10, 2021	$-41.63	$-16.68	+59.9%	✓ BEAT
Q2 2021	May 14, 2021	$-25.94	$-19.92	+23.2%	✓ BEAT
Q1 2021	Feb 12, 2021	—	$-29.02	—	—
Q4 2020	Nov 13, 2020	—	$-27.35	—	—